Detoxification enzyme polymorphisms as risk factors fo t-AML

Published: June 16, 2009
Abstract Views: 220
PDF: 271
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Todate, therapy-related myelodysplastic syndromes/acute Myeloid Leukemias (t-MDS/ AML) represent the main long-term adverse effect of cancer treatment. The identification of new prognostic factors has raised the question whether reducing treatment intensity in good prognosis patients may save them from long term-toxicity, without impairing response rates.

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Supporting Agencies

How to Cite

Voso, M. T., D’Alò, F., & Leone, G. (2009). Detoxification enzyme polymorphisms as risk factors fo t-AML. Hematology Meeting Reports (formerly Haematologica Reports), 2(15). https://doi.org/10.4081/hmr.v2i15.604